Evaluation of Mirikizumab in Pediatric Patients with Moderately to Severely Active Crohn's Disease: A Phase 3 Randomized Multicenter Study

The primary objective of this Phase 3, multicenter, randomized clinical study is to evaluate the efficacy of **IL-23 inhibitors**, specifically Mirikizumab, in achieving clinical remission and endoscopic response in pediatric participants with moderately to severely active **Crohn's Disease** (CD) at Week 52. This evaluation is crucial as it aims to determine the superiority of Mirikizumab over adult placebo in managing CD without the need for modification of investigational product (IP) regimen, IP rescue therapy, or non-IP rescue therapy. The clinical relevance of this study lies in its potential to provide a more effective treatment option for pediatric patients suffering from this chronic inflammatory bowel disease, thereby improving their quality of life and long-term health outcomes.

The clinical trial involves a total of **58 participants** diagnosed with **Crohn's Disease**, specifically targeting a pediatric population with moderately to severely active disease. The study includes both male and female subjects, with an age range that encompasses children and adolescents. Participants were selected based on a confirmed diagnosis of Crohn's Disease or fistulizing Crohn's Disease, with active colitis, ileitis, or ileocolitis, verified through clinical, endoscopic, and histologic criteria. The trial population includes individuals who have shown an inadequate response, loss of response, or intolerance to previous treatments, including immunomodulators, corticosteroids, biologic therapy, or JAK inhibitors. The study considers vulnerable populations, ensuring comprehensive evaluation and monitoring. Lifestyle factors such as diet and physical activity are not specified, but the inclusion criteria emphasize the necessity of a documented history of treatment challenges. The trial aims to assess the efficacy of IL-23 inhibitors compared to placebo in achieving clinical remission and endoscopic response over a 52-week period.

The clinical trial is designed to evaluate the efficacy and safety of **Mirikizumab** in pediatric participants with moderately to severely active **Crohn's Disease**. This is a Phase 3, multicenter, randomized, double-blind, controlled study. The trial aims to assess whether treatment with IL-23 inhibitors is superior to placebo in achieving clinical remission and endoscopic response at Week 52. The study is expected to last until August 2028, with recruitment starting in February 2024. Participants will be involved for a maximum of 52 weeks, during which they will receive **Mirikizumab** in the form of a solution for injection via cutaneous, subcutaneous, or intravenous routes.

The trial includes several key visits: an initial screening visit to confirm eligibility based on criteria such as a diagnosis of **Crohn's Disease** and evidence of active disease, followed by regular follow-up visits to monitor clinical response and safety. The primary endpoints include the percentage of participants achieving a clinical response by the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and an endoscopic response by the Simple Endoscopic Score for CD (SES-CD) at Week 52. The end-of-study visit will assess the overall outcomes and any adverse events experienced during the trial.

Participants may be withdrawn from the study early if they require modification of the investigational product regimen, rescue therapy, or if they experience significant adverse events. The trial's design ensures that all procedures adhere to rigorous scientific and ethical standards, providing valuable data on the potential benefits of **Mirikizumab** for pediatric patients with **Crohn's Disease**.

The clinical trial involves the administration of **Mirikizumab**, a **solution for injection** developed by Eli Lilly and Company Limited. Mirikizumab is an investigational medication being evaluated for its efficacy in treating pediatric patients with moderately to severely active Crohn's Disease. The active substance, mirikizumab, is a protein-based compound classified under "Protein - Other." The pharmaceutical form of the medication is a solution for injection, and it is not a pediatric-specific formulation. The maximum treatment period for the trial is 52 weeks.

Mirikizumab is administered through three different routes: cutaneous use, subcutaneous use, and intravenous use. The specific dosage and frequency of administration are not explicitly defined in the trial data, as the maximum daily and total dose amounts are indicated as zero. This suggests that dosing may be adjusted based on individual patient needs or other trial-specific criteria. Participant compliance with the dosing schedule will be monitored throughout the study to ensure adherence to the treatment protocol.

In this trial, no non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatments are mentioned. The focus is solely on evaluating the effects of Mirikizumab in achieving clinical remission and endoscopic response in the target patient population. The trial aims to determine whether treatment with IL-23 inhibitors, such as Mirikizumab, is superior to adult placebo in achieving the desired clinical outcomes without the need for modification of the investigational product regimen or rescue therapy.

Efficacy in the clinical trial evaluating **Mirikizumab** for pediatric Crohn's Disease will be assessed using specific primary endpoints. These endpoints include the percentage of participants achieving a clinical response by the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and an endoscopic response by the Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 52. Additionally, the trial will measure the percentage of participants achieving clinical remission by PCDAI at Week 52. The clinical response and remission will be evaluated from baseline to Week 52.

The trial aims to determine whether treatment with IL-23 inhibitors is superior to placebo in achieving clinical remission and endoscopic response in pediatric participants with moderately to severely active Crohn's Disease at Week 52. The assessments will be conducted at specified time points, including Week 12 and Week 52, using validated scales such as PCDAI and SES-CD to ensure accurate measurement of efficacy outcomes.